VITRO BIOPHARMA, INC.: operating cash flow

What this measure means

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-11-01 to 2025-10-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• VITRO BIOPHARMA, INC.: total assets
• VITRO BIOPHARMA, INC.: total liabilities
• VITRO BIOPHARMA, INC.: stockholders equity
• VITRO BIOPHARMA, INC.: cash and cash equivalents
• VITRO BIOPHARMA, INC.: net income or loss
• VITRO BIOPHARMA, INC.: capital expenditure payments
• VITRO BIOPHARMA, INC.: revenue
• VITRO BIOPHARMA, INC.: contract revenue excluding tax
• VITRO BIOPHARMA, INC.: financing cash flow
• VITRO BIOPHARMA, INC.: investing cash flow
• VITRO BIOPHARMA, INC.: retained earnings or deficit
• VITRO BIOPHARMA, INC.: basic weighted-average shares
• VITRO BIOPHARMA, INC.: diluted weighted-average shares
• VITRO BIOPHARMA, INC.: basic earnings per share
• VITRO BIOPHARMA, INC.: diluted earnings per share
• VITRO BIOPHARMA, INC.: net property, plant and equipment
• VITRO BIOPHARMA, INC.: share-based compensation expense
• VITRO BIOPHARMA, INC.: operating income or loss
• VITRO BIOPHARMA, INC.: current assets
• VITRO BIOPHARMA, INC.: interest expense
• VITRO BIOPHARMA, INC.: current liabilities
• VITRO BIOPHARMA, INC.: current accounts payable
• VITRO BIOPHARMA, INC.: goodwill carrying amount
• VITRO BIOPHARMA, INC.: net finite-lived intangible assets
• VITRO BIOPHARMA, INC.: net current accounts receivable
• VITRO BIOPHARMA, INC.: net inventory
• VITRO BIOPHARMA, INC.: gross profit
• VITRO BIOPHARMA, INC.: selling, general and administrative expense
• VITRO BIOPHARMA, INC.: research and development expense
• VITRO BIOPHARMA, INC.: common shares outstanding
• VITRO BIOPHARMA, INC.: cash including restricted cash
• VITRO BIOPHARMA, INC.: additional paid-in capital
• VITRO BIOPHARMA, INC.: total equity including noncontrolling interests
• VITRO BIOPHARMA, INC.: operating lease right-of-use asset
• VITRO BIOPHARMA, INC.: operating lease liability
• VITRO BIOPHARMA, INC.: long-term debt
• VITRO BIOPHARMA, INC.: gross property, plant and equipment
• VITRO BIOPHARMA, INC.: accumulated depreciation on property, plant and equipment
• VITRO BIOPHARMA, INC.: net intangible assets excluding goodwill
• VITRO BIOPHARMA, INC.: other noncurrent assets
• VITRO BIOPHARMA, INC.: accrued current liabilities
• VITRO BIOPHARMA, INC.: pre-tax income or loss from continuing operations
• VITRO BIOPHARMA, INC.: profit or loss including noncontrolling interests
• VITRO BIOPHARMA, INC.: net income available to common stockholders
• VITRO BIOPHARMA, INC.: depreciation expense
• VITRO BIOPHARMA, INC.: depreciation, depletion and amortization
• VITRO BIOPHARMA, INC.: amortization of intangible assets
• VITRO BIOPHARMA, INC.: nonoperating interest expense
• VITRO BIOPHARMA, INC.: interest paid, net
• VITRO BIOPHARMA, INC.: operating lease payments
• VITRO BIOPHARMA, INC.: change in accounts receivable
• VITRO BIOPHARMA, INC.: change in inventories

Inspect the source

Entity

VITRO BIOPHARMA, INC. / CIK 0000793171

Captured

2026-09-21T17:17:03.076Z

SEC response SHA-256

e4a45888e3fd56bf245fee78b2235f6f8d9c94b7a357b46c64ff1e0e8b6cac32

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000793171.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))